Study S000512

A Randomized Parallel Comparison of Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04979130
Acronym: SIB
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 69
Start: 2022-01-01
Primary completion: 2024-10-16
Lead sponsor: University of Colorado, Denver
Conditions: Type 2 Diabetes; Chronic Inflammation; Intestinal Permeability
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups [Week 16 (visit 6)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015240	Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus. Rella S, Therapeutic advances in endocrinology and metabolism	2023	Protocol	PMID 37916028 DOI	cites ClinicalTrials.gov:NCT04979130